drugset / Trial / NCT01164605

Pilot Study of Raltegravir Lipodystrophy IISP

NCT01164605

NaSingle-groupOpen-labelTreatment

Summary

The substitution of raltegravir for the NRTIs will result in some reversal of the long term adverse effect of lipodystrophy (specifically peripheral lipoatrophy) that is associated with the chronic use of NRTIs. Changing the HAART regimen in patients with a sustained virological response from a PI plus NRTI to a regimen of the PI plus raltegravir will likely result in continued virologic efficacy.

Timeline

Start
2010-10
Primary completion
2013-06
Completion
2013-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Raltegravir Other / unclassified